TY - JOUR
T1 - European guideline for imaging of primary paediatric and adult osteosarcoma and Ewing sarcoma
T2 - systematic review and joint statement by the FOSTER consortium, Euro Ewing Consortium, European Society of Paediatric Radiology, and the European Association of Nuclear Medicine
AU - Adriaansen, Laura M.E.
AU - Merks, Johannes H.M.
AU - van Dalen, Elvira C.
AU - Andersen, Kim F.
AU - Asaftei, Sebastian D.
AU - Bernabeu, Daniel
AU - Boye, Kjetil
AU - Campello, Anna
AU - Capra, Michael
AU - Costa Dias, Sílvia
AU - Dávila Fajardo, Raquel
AU - Dziuk, Miroslaw
AU - van Ewijk, Roelof
AU - Gaspar, Nathalie
AU - Gerrand, Craig
AU - Herrmann, Ken
AU - Isnardi, Vanina
AU - Jehanno, Nina
AU - von Kalle, Thekla
AU - Lancharro Zapata, Angel M.
AU - van Langevelde, Kirsten
AU - Morland, David
AU - Mulder, Renée L.
AU - Palmerini, Emanuela
AU - Rajesparan, Kannan
AU - Rogasch, Julian M.M.
AU - Safwat, Akmal
AU - Sirvent Cerdá, Sara
AU - Spinnato, Paolo
AU - Strauss, Sandra J.
AU - Vieth, Volker
AU - Vöö, Stefan
AU - Woering, Megan P.
AU - ter Horst, Simone A.J.
AU - Braat, Arthur J.A.T.
AU - van Rijn, Rick R.
N1 - Publisher Copyright:
© 2026 Elsevier Ltd.
PY - 2026/7
Y1 - 2026/7
N2 - Imaging is central to diagnosing, staging, evaluating treatment response, and guiding post-therapy surveillance in osteosarcoma and Ewing sarcoma, yet no international consensus defines optimal modalities or schedules. This European guideline, developed by 36 multidisciplinary experts, seeks to standardise imaging for research and enhance patient care. A systematic review identified 2026 studies, of which 13 met criteria, revealing marked heterogeneity in diagnoses, chemotherapy regimens, and imaging protocols. Evidence remains inconclusive regarding the optimal modality for detecting bone metastases, and no metabolic imaging indices or MRI parameters consistently predict response or survival. Data are similarly insufficient to define the ideal frequency of post-treatment surveillance. Recommendations for clinical practice were formulated according to International Guideline Harmonization Group standards, based on evidence and expert opinion. In total, 32 consensus-based recommendations were issued. Substantial evidence gaps persist, underscoring the need for international prospective imaging studies to establish robust, harmonised standards for future patient care.
AB - Imaging is central to diagnosing, staging, evaluating treatment response, and guiding post-therapy surveillance in osteosarcoma and Ewing sarcoma, yet no international consensus defines optimal modalities or schedules. This European guideline, developed by 36 multidisciplinary experts, seeks to standardise imaging for research and enhance patient care. A systematic review identified 2026 studies, of which 13 met criteria, revealing marked heterogeneity in diagnoses, chemotherapy regimens, and imaging protocols. Evidence remains inconclusive regarding the optimal modality for detecting bone metastases, and no metabolic imaging indices or MRI parameters consistently predict response or survival. Data are similarly insufficient to define the ideal frequency of post-treatment surveillance. Recommendations for clinical practice were formulated according to International Guideline Harmonization Group standards, based on evidence and expert opinion. In total, 32 consensus-based recommendations were issued. Substantial evidence gaps persist, underscoring the need for international prospective imaging studies to establish robust, harmonised standards for future patient care.
UR - https://www.scopus.com/pages/publications/105043027211
U2 - 10.1016/S1470-2045(26)00141-5
DO - 10.1016/S1470-2045(26)00141-5
M3 - Review article
AN - SCOPUS:105043027211
SN - 1470-2045
VL - 27
SP - e339-e349
JO - The Lancet Oncology
JF - The Lancet Oncology
IS - 7
ER -